**Name of Journal:** ***World Journal of Gastroenterology***

**Manuscript NO: 47067**

**Manuscript Type:** **MINIREVIEWS**

**Identifying high-risk individuals for gastric cancer surveillance from western and eastern perspectives: Lessons to learn and possibility to develop an integrated approach for daily practice**

Quach DT *et al.* Identifying high-risk individuals for GC surveillance

Duc Trong Quach, Toru Hiyama, Takuji Gotoda

**Duc Trong Quach,** Department of Internal Medicine, University of Medicine and Pharmacy at Hochiminh City, Ho Chi Minh 70000, Vietnam

**Toru Hiyama,** Health Service Center, Hiroshima University, Higashihiroshima 739-8514, Japan

**Takuji Gotoda,** Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Tokyo 101-8309, Japan

**ORCID number:** Duc Trong Quach (0000-0003-0141-921X); Toru Hiyama (0000-0002-5843-232X); Takuji Gotoda (0000-0001-6904-6777).

**Author contributions**: Quach DT contributed to study conception and design of the study. All authors contributed to literature review and analysis, drafting and critical revision and editing, and final approval of the final version.

**Conflict-of-interest statement:** No potential conflicts of interest. No financial support.

**Open-Access:** This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Corresponding author: Duc Trong Quach, MD, PhD, Associate Professor, Attending Doctor, Senior Lecturer,** Department of Internal Medicine, University of Medicine and Pharmacy at Hochiminh City, 217 Hong Bang Street, District 5, Ho Chi Minh 70000, Vietnam. drquachtd@ump.edu.vn

**Telephone:** +84-8-38554269

**Fax:** +84-8-39506126

**Received:** March 11, 2019

**Peer-review started:** March 11, 2019

**First decision:** May 9, 2019

**Revised:** May 28, 2019

**Accepted:** June 22, 2019

**Article in press:** June23, 2019

**Published online:** July 21, 2019

**Abstract**

Current evidence shows that individuals with gastric dysplasia, severe and extensive gastric atrophy, extensive gastric intestinal metaplasia and the incomplete subtype of intestinal metaplasia are at high risk for gastric cancer (GC) development. There are several approaches to identifying these subjects, including noninvasive methods, esophagogastroduodenoscopy and histology. The main approach in Western countries is histology-based while that in Eastern countries with a high prevalence of GC is endoscopy-based. Regarding asymptomatic individuals, the key issues in selecting applicable approaches are the ability to reduce GC mortality and the cost-effectiveness of the approach. At present, population-based screening programs have only been applied in a few Asian countries with a high risk of GC. Pre-endoscopic risk assessment based on demographic and clinical features, such as ethnicity, age, gender, smoking and *Helicobacter pylori* status, is helpful for identifying subjects with high pre-test probability for a possibly cost-effective approach, especially in intermediate- and low-risk countries. Regarding symptomatic patients with indications for esophagogastroduodenoscopy, the importance of opportunistic screening should be emphasized. The combination of endoscopic and histological approaches should always be considered as endoscopy provides a real-time assessment of the patient’s risk level. In addition, imaging enhanced endoscopy (IEE) has been shown to facilitate targeted biopsies resulting in better correlation between endoscopic and histological findings. Currently, the use of IEE is recommended for endoscopic examinations, and the Operative Link for Gastric Intestinal Metaplasia or Operative Link on Gastritis Assessment grading systems are recommended for histological examinations whenever available. However, resource limitations are an important barrier in many regions worldwide. Thus, for an approach to be applicable in real-life practice, it should be not only evidence-based but also resource-sensitive. In this review, we discuss the current understanding and approaches to identifying high-risk individuals from western and eastern perspectives, as well as the possibility of an integrated, resource-sensitive approach.

**Key words:** Gastric cancer; Precancerous gastric lesions; Dysplasia; Gastric atrophy; Chronic atrophic gastritis; Intestinal metaplasia; Dysplasia; Surveillance; Screening; Cost-effective

**© The Author(s) 2019.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Current evidence shows that patients with gastric dysplasia, severe and extensive gastric atrophy, extensive gastric intestinal metaplasia and the incomplete subtype of intestinal metaplasia are at high risk for gastric cancer development. Key issues in selecting approaches to identifying these subjects are the ability to reduce gastric cancer mortality and cost-effectiveness of the approach. Resource limitations are an important barrier in many regions worldwide. Thus, an applicable approach in real-life practice should be not only evidence-based but also resource-sensitive. In this review, we discuss the current understanding from western and eastern perspectives, and the possibility of an integrated, resource-sensitive approach.

**Citation**: Quach DT, Hiyama T, Gotoda T. Identifying high-risk individuals for gastric cancer surveillance from western and eastern perspectives: Lessons to learn and possibility to develop an integrated approach for daily practice. *World J Gastroenterol* 2019; 25(27): 3546-3562

**URL**: https://www.wjgnet.com/1007-9327/full/v25/i27/3546.htm

**DOI**: https://dx.doi.org/10.3748/wjg.v25.i27.3546

**INTRODUCTION**

With approximately 1.0 million new cases diagnosed in 2018, gastric cancer (GC) is currently the 5th most common cancer worldwide[1]. However, it is the third leading cause of cancer-related death as the majority of patients are diagnosed at an advanced stage. The detection of GC at an early stage is crucial, as the 5-year survival rate of GC patients is significantly better when it is managed in the early stages[2]. Furthermore, therapeutic endoscopy techniques, such as endoscopic mucosal resection and endoscopic submucosal dissection have been successfully applied to cure patients suffering from early GC, thereby allowing the patients to avoid the risks associated with surgery.

Diagnosing the disease at an early stage is challenging, as many GC patients are asymptomatic in the early stages and in some cases patients with advanced-stage disease may have no alarming features[3-5]. As the development of GC is usually preceded by the decades-long progression of a precancerous lesion[6] and the progression of GC from the early to advanced stages takes an average of 44 mo[7], it is important to identify high-risk individuals and to offer them a proper surveillance program.

Current evidence shows that individuals with gastric dysplasia, high-stage gastritis [according to the Operative Link on Gastritis Assessment (OLGA) or Operative Link for Gastric Intestinal Metaplasia (OLGIM)], severe endoscopic gastric atrophy (EGA), extensive gastric intestinal metaplasia (GIM) and the incomplete subtype of GIM are at increased risk for GC development[8-12]. In addition, it is reported that *Helicobacter pylori* (*H. pylori*) eradication does not reduce the GC risk of these individuals[13]. Thus, individuals with these conditions are at high risk for developing gastric cancer and should be identified and offered proper surveillance.

There are several approaches to identifying high-risk individuals, including noninvasive methods, esophagogastroduodenoscopy (EGD) and histology. The main approach in western countries is histology-based while that in Eastern countries with high prevalence of GC is endoscopy-based. One important issue that affects these approaches is cost-effectiveness. Another important and challenging issue, which has not received much attention in current literature, is local resources, as there are some regions with in which the risk of GC is high but resources are limited (Figure 1). In this review, we discuss the current understanding and approaches from western and eastern perspectives and the possibility of implementing an integrated, resource-sensitive approach.

**IDENTIFYING HIGH-RISK INDIVIDUALS FOR GASTRIC CANCER DEVELOPMENT**

There are several approaches to identifying subjects at high risk for gastric cancer development, including noninvasive methods, EGD and histology. A histological examination is traditionally required for the diagnosis of precancerous gastric lesions. However, endoscopy, especially with modern endoscopic technologies, and biomarkers have been reported to have acceptable accuracy in the histological diagnosis of precancerous gastric lesions. Currently, the main approach in Western countries is histology-based while that in Eastern countries with a high prevalence of GC is endoscopy-based.

***The histological approach***

**Gastric atrophy and the risk of GC development:** One of the first systematic reviews to describe the risk of GC in patients with histologically diagnosed gastric atrophy was recently published[14]. This study, which consisted of 5 studies from Europe and three studies from Asia, found that the annual incidence of GC among patients with gastric atrophy ranged from 0.1% to 0.5%. In addition, it found that patients with gastric atrophy in Asia had a higher risk of GC in comparison to those in Europe.

Atrophy of the gastric mucosa was traditionally deﬁned as the loss of glands[15]. However, agreement among pathologists on the recognition and grading of gastric atrophy has remained elusive when using this definition[16]. Subsequently, it was re-defined as the loss of appropriate glands, which led to a high level of agreement among gastrointestinal pathologists trained in different cultural contexts[17]. In addition, although the updated Sydney system of gastritis classification has been accepted worldwide, it lacks prognostic information. Consequently, the OLGA gastritis staging system, which is based on the understanding that the risk levels of GC are directly related to the extent and severity of gastric atrophy, was proposed[18]. This atrophy-based staging system combines the antral and oxyntic mucosal atrophy scores using the updated Sydney system visual analog scales with the aim of offering clinicians information about the risk of GC[19]. A multi-center study has been conducted to test the correlation between the stages of gastritis, classified according to this staging system, with the risk of GC in different populations[20]. This study showed that the OLGA stage of gastritis mirrored the incidence of GC in populations with different levels of GC risk. Observational studies from populations with different levels of GC risk also consistently showed that neoplastic gastric lesions clustered in high stages (*i.e.*,stage III and IV) OLGA gastritis, supporting the potentially useful application of the system in clinical practice[21, 22]. In a prospective cross-sectional study of 439 consecutive dyspeptic outpatients in Italy who underwent endoscopy with standardized biopsy sampling, benign conditions were consistently clustered in OLGA stages 0-II, whereas all neoplastic gastric lesions were clustered in OLGA stages III-IV[21]. In another cross-sectional study to assess the distribution of the OLGA gastritis stages of 280 non-ulcer dyspeptic patients in Vietnam, neoplastic lesions were found to cluster in patients with OLGA stages III-IV as opposed to OLGA stages 0-II[22]. A meta-analysis of 6 case-control studies and 2 cohort studies from Europe and Asia also showed that there was a significant association between OLGA stages III-IV and GC[12]. Recently, two large and long-term follow-up Italian studies confirmed that this staging system reliably predicts the risk of GC development[23, 24]. The Kyoto global consensus on *H. pylori* gastritis strongly recommends the use of the OLGA and OLGIM grading systems for GC risk stratification[10].

In summary, the application of the new definition of gastric atrophy as the loss of inappropriate glands has led to have a higher agreement in the assessment of gastric atrophy. The risk of GC is significantly associated with the extent and severity of gastric atrophy, and the OLGA staging system has been shown to be correlated with risk of GC in long-term cohort studies.

**GIM and the risk of GC development:** A nationwide cohort study in the Netherlands reported that the overall annual incidence of GC development in patients with GIM was 0.25% at 5 years[25]. A population-based cohort study in Sweden reported that approximately 1 in 39 patients with GIM who underwent EGD with gastric biopsy for non-malignant indications developed GC within 20 years[26]. In a recent systematic review consisting of 9 cohorts (4 from the United States, 4 from Western European countries and 1 from South Korea), the incidence of GC among patients with GIM ranged from 0.38 to 17.08 per 1000 person-years[14]. However, the majority of the included cohorts reported incidence rates between 1.26 and 4.10 per 1000 person-years.

**GIM subtypes and the risk of GC development:** GIM can be classified into complete and incomplete subtypes. The complete subtype (type I) is characterized by goblet cells scattered among columnar absorptive cells. The incomplete subtype is characterized by goblet cells interspersed among mucin-secreting columnar cells, which can be further divided into type II (sialomucin-secreting cells; presence of Paneth cells) and type III (sulphomucin-secreting columnar cells; absence of Paneth cells) by high-iron diamine staining[27].

A cancer registry-based study in Slovenia reported that the cumulative incidence of GC in patients previously diagnosed with GIM was 1.3% in complete GIM type I, 2.8% in incomplete GIM type II and 9.8% in incomplete GIM type III[27]. A Spanish study reported that GC developed in 18.2% of patients with incomplete GIM and in only 0.9% of patients with complete GIM after a mean follow-up period of 12.8 years[28]. This study showed—based on a multivariate analysis—that incomplete GIM was associated with the highest risk of developing GC (Hazard ratio 11.3, 95%CI: 3.8-33.9). In South Korea, GIM subtyping was not been found to play a major role in the prediction of GC development[29]. However, these observations were derived from cross-sectional studies and results from follow-up studies are awaited.

In a literature review on the association between incomplete GIM and GC in studies published between 1980 and 2010, 13 of the 14 cross-sectional studies and 6 of the ten follow-up studies found a statistically significant association between incomplete GIM and the risk of GC[30]. Among the studies that reported the magnitude of the risk, the relative risk (RR) of GC in patients with incomplete GIM was 4- to 11-fold higher than that in patients with complete GIM or without incomplete-type GIM.

In a recent retrospective cohort study in Thailand, 91 patients with GIM were recruited for surveillance EGD every 6-12 mo until a diagnosis of GC was made or the planned 5‐year follow-up period was completed[31]. By the end of the study, incomplete GIM and male sex were found to be significantly associated with the development of gastric neoplasia. None of the 81 patients with complete GIM at the time of recruitment developed GC. In contrast, 5 of the 10 patients exhibiting incomplete GIM progressed to high-grade dysplasia (HGD) and GC.

In summary, most of the scientific evidence supports that incomplete GIM is a risk factor for GC.

**The extent of GIM and the risk of GC development:** The extent of GIM is a very important risk factor for the development of GC. There are four patterns of GIM distribution[32]. The “focal” GIM pattern consists of scattered foci, mostly in the lesser curvature and incisura. The “antrum-predominant” GIM pattern involves most of the antrum and incisura angularis. The “magenstraße” GIM pattern spreads throughout the lesser curvature from the cardia to the pylorus, also involving the greater curvature of the pre-pyloric antrum. Finally, the “diffuse” GIM pattern involves the entire gastric mucosa, with the exception of the fundic areas. In comparison to the focal or antral-predominant GIM patterns, the magenstraße GIM and diffuse GIM patterns are associated with a 5.7-fold and 12.2-fold increase in the risk of GC development, respectively. An Italian study also reported that the extension of GIM was associated with the risk of GC, and that ≥ 20% baseline GIM extension was a sensitive first screening parameter for identifying subjects with a higher risk of GC[33]. Recently, a Japanese cohort study followed 573 patients for 6.2 years and found that GC developed in 21 patients[34]. The cumulative 5-year incidence of GC was 1.5% in patients without GIM, 5.3% in those with GIM limited to the antrum and 9.8% in those with GIM in the corpus.

**The OLGIM staging system:** The proposed OLGIM staging system is based on the OLGA staging system, which provides clinically relevant information about gastric intestinal metaplasia[35]. The main parameter of this system is the severity and extent of GIM, rather than gastric atrophy. The rationale for this system is that previous studies reported that the degree of interobserver agreement in the assessment of gastric atrophy was lower in comparison that for the assessment of GIM[36,37].

A prospective multicenter study conducted in Netherlands found that replacement of gastric atrophy by GIM in the staging of gastritis considerably increased interobserver agreement while the correlation with the severity of gastritis remained at least as strong[35]. A systematic review and meta-analysis on the association between the OLGIM gastritis stage and the GC risk has been recently published[12]. The meta-analysis, which was based on three case-control studies from Eastern countries, showed that the GC risk was significantly higher among patients with OLGIM stage III-IV [Odds ratio (OR) = 3.99; 95%CI: 3.05-5.21: *P* < 0.001]. The only prospective cohort study, which was conducted in the Netherlands, found that patients with OLGIM stage III-IV were more likely to develop HGD (RR = 16.67; 95%CI: 0.8-327.53).

**Gastric dysplasia and the risk of GC development:** Gastric dysplasia is usually classified as low or high grade[38]. A nationwide cohort study in the Netherlands reported that the annual incidence of GC in patients with LGD and HGD within 5 years after the diagnosis was 0.6% and 6%, respectively[39]. A recent population based cohort study in Sweden reported that 1 in 19 patients with dysplasia progressed to GC within 20 years, although no differentiation was made between those with low-grade dysplasia (LGD) or high-grade dysplasia (HGD)[26]. Notably, there is a remarkably histological discrepancy between biopsy specimens and material obtained from endoscopic resection. A recent study from Japan found that a substantial proportion of biopsy-proven gastric LGD specimens were diagnosed as GC after endoscopic resection[40]. The strategy for managing patients with gastric dysplasia is therefore more straightforward in comparison to that for gastric atrophy and GIM. The resection of endoscopically visible dysplastic lesions is now recommended worldwide, regardless of the grade of dysplasia[9,11,41]. However, a considerable number of patients have endoscopically invisible gastric dysplasia. These patients are still at high risk and need to be strictly followed up[22,42]. A recent literature review reported that LGD persisted in 19%-50% of patients and that the risk of GC development in these patients ranged from 0% to 23% over 10-48 mo[11]. Regarding endoscopically invisible HGD, immediate endoscopic reassessment with extensive biopsy sampling and surveillance at 6- to 12-mo intervals is mandatory. Furthermore, the disappearance or assumed disappearance of dysplastic lesions, as assessed by follow-up endoscopic biopsy, does not rule out possible progression to invasive GC[9,41].

***Endoscopic approaches***

**White light endoscopy:** Gastric atrophy: The endoscopic diagnosis of gastric atrophy based on the good visualization of the submucosal vessels, even in the hands of experienced endoscopists, is not reliable[43]. The sensitivity and specificity were only 61.5% and 57.7%, respectively in the antrum; and 46.8% and 76.4%, respectively in the corpus. However, the assessment of EGA according to the Kimura-Takemoto classification has been consistently confirmed to have a good correlation with histological gastric atrophy[22,44]. In addition, several long-term cohort studies confirmed its value in predicting the risk of GC development in subjects with and without *H. pylori* infection, as well as after thesuccessful eradication of *H. pylori*[8,34,45].

The key point in assessing EGA according to the Kimura-Takemoto classification is to identify the location of the so-called endoscopic atrophic border of the stomach[46]. Based on the location of the endoscopic atrophic border, an endoscopic classification of gastric atrophy pattern was proposed which consists of two main types: closed type (C type) and open type (O type). These two types are further subdivided in into three C-types (C-1, C-2 and C-3) and three O-types (O-1, O-2 and O-3). The severity of endoscopic gastric atrophy (EGA) is often classified into three grades: mild (C-1, C-2), moderate (C-3, O-1) and severe (O-2, O-3)[8,22,34,45]. Our previous study in Vietnam showed that the severity of EGA was signiﬁcantly correlated with the OLGA gastritis stage[22]. As EGA assessment has not been widely applied in Western countries and it was unclear whether the EGA findings are correlated with histological atrophy in Western patients, another study was conducted in the United Kingdom[44]. In this study, EGA was compared with histological atrophy using the updated Sydney classification system. The strength of agreement on the extent of atrophy between the endoscopic and histological findings was good, with a weighted kappa value of 0.76. In addition, the strength of agreement between endoscopic and histological atrophy, as assessed by cancer risk-oriented grading (*i.e.,* none, limited atrophy in antrum and angulus or pan-atrophy) was good, with a kappa value of 0.81.

Several studies have consistently confirmed that the severity of EGA at baseline is associated the risk of GC development. A prospective cohort study that followed 1,603 consecutive Japanese patients with benign gastroduodenal diseases for an average of 8 years found that GC only developed in patients with *H. pylori* infection, and the RR of GC in patients with severe EGA at baseline was 4.9 times higher than that of those with no or mild EGA at baseline[8]. A recent cohort study that included 573 Japanese patients who underwent follow-up endoscopy after successful *H. pylori* eradication therapy found that the cumulative 5-year incidence of GC was 0.7%, 1.9%, and 10% in patients with the no/mild, moderate, and severe EGA, respectively[34]. Based on the current evidence, the Kyoto global consensus on gastritis suggested that EGA assessment can be used initially in regions with proven expertise in EGA assessment; however, histological conﬁrmation is still recommended[10].

GIM: The endoscopic diagnosis of GIM by standard endoscopy is also unreliable even in the hands of experienced endoscopists. A study in Korea reported that the sensitivity and specificity of endoscopy for the diagnosis of GIM were 24.0% and 91.9%, respectively for the antrum; 24.2% and 88.0%, respectively for the body[47]. A another study in Greece reported that the sensitivity and specificity of endoscopy for the diagnosis of GIM and LGD were 74.6% and 94%, respectively[48].

Gastric dysplasia: The endoscopic diagnosis of gastric dysplasia by endoscopy is even more unreliable, especially for LGD. In a Finnish study that included a series of 101 patients with histologically diagnosed gastric dysplasia graded into three categories (mild, moderate, or severe), all severe dysplastic lesions were detected in visible lesions but three (22%) moderate dysplastic lesions and 57 (68%) mild dysplastic lesions were endoscopically invisible and were only detected in random biopsy specimens[42]. Our previous study of 280 dyspeptic patients in Vietnam identified LGD in 7 (2.5%) patients and all of cases, these lesions were endoscopically invisible[22].

**IEE and magnifying endoscopy:** Several studies have shown the significantly higher accuracy of IEE and magnification endoscopy in the diagnosis of gastric atrophy, GIM, dysplasia and GC in comparison to WLE. A multicenter prospective randomized study in the Asia-Paciﬁc region was conducted to compare the narrow-band imaging (NBI) and high-definition WLE (HD-WLE) in the detection of GIM[49]. This study found that a significantly higher proportion of patients with GIM was detected by NBI compared with HD-WLE (17.7% *vs* 7.7%, *P* < 0.001). Similarly, a recent prospective blinded trial in the United States reported higher proportions of patients with GIM were detected by NBI (65%) and mapping (76%) *vs* HD-WL (29%) (*P* < 0.005 for both comparisons). In addition, there were also higher proportions of sites with GIM detected with NBI (53%) and mapping biopsies (67%) than HD-WL (28%) (*P* < 0.005 for both comparisons). A recent consensus developed by expert endoscopists in Asia strongly recommends to use IEE in addition to WLE to improve the detection rate of precancerous gastric lesions[50].

The development of NBI magnifying endoscopy (NBI-ME) has helped endoscopists to better observe the gastric mucosa endoscopically. The Light Blue Crest (LBC) sign, defined as a fine, blue-white line on the crests of the epithelial surface/gyri, was found to correlate with histological evidence of GIM[51]. A recent meta-analysis on the diagnostic yield of LBC in GIM reported that the sensitivity and specificity value of this finding were 0.90 (95%CI: 0.86-0.92) and 0.90 (95%CI: 0.86-0.93), respectively[52]. The practicality of NBI-ME for gastritis staging has been reported in Japan[53]. In this study, the NBI-ME score classification was established from images obtained beforehand, and then biopsy specimens taken from the observed areas were scored according to histological findings. The NBI-ME and histological stages were assessed using a combination of scores for the antrum and corpus, and were divided into low-risk and high-risk groups. This study found that the agreement between NBI-ME and histological scores was 69.1% for the antrum and 72.7% for the corpus, and that between the high- and low-risk groups was 89.1%. NBI-ME procedures, however, are generally time-consuming and require appropriate training and gastroscope. Therefore, it could not be widely used in daily practice.

A simplified classification system using NBI without magnification has been proposed and validated in Western countries, and its accuracy and reliability in the diagnosis of GIM and dysplasia have been demonstrated[54]. According to the simplified classification, pattern A (regular vessels with circular mucosa) was associated with normal histology (accuracy 83%; 95%CI: 75%-90%), pattern B (tubulo-villous mucosa) was associated with GIM (accuracy 84%; 95%CI: 77%-91%); and pattern C (irregular vessels and mucosa) was associated with dysplasia (accuracy 95%; 95%CI: 90%-99%). The reproducibility of these patterns was high (k = 0.62). Non-experienced endoscopists showed lower agreement (k = 0.6 *vs* k = 0.75) and accuracy (74 % *vs* 86%) than experienced endoscopists, suggesting that appropriate training is required. The real-time validity of HD-WLE with and without NBI in the diagnosis of precancerous gastric lesions and the possibility of deriving a classification for the endoscopic grading of GIM (EGGIM), a score (0-10) resulting from the sum of endoscopic assessments of GIM, have been reported[55,56]. In a later multicenter prospective study, NBI based on the simplified classification was found to significantly increase sensitivity in the diagnosis of GIM and gastric dysplasia (87% *vs* 53% and 92% *vs* 74%, respectively). The area under the curve (AUC) of the receiver operating characteristic curve for EGGIM in the diagnosis of extensive GIM was 0.98[55]. Another study was conducted by the same group to externally validate the EGGIM classification[56]. Consecutive patients underwent HD-WLE followed by NBI to estimate the EGGIM classification. The score was 0, 1, or 2 for no GIM, ≤ 30%, or > 30% of the mucosa, respectively, in five areas (lesser and greater curvature of both the antrum and corpus, and incisura). If GIM was endoscopically suspected, targeted biopsies were performed. If GIM was not noticeable, random biopsies were performed according to the Sydney system to estimate the OLGIM stage. For the diagnosis of high-stage OLGIM gastritis, the AUC was 0.96 (95%CI: 0.93-0.98) and the sensitivity and specificity using a cutoff of > 4 were 89% and 95%, respectively. This study shows the promise of the endoscopic approach in determining the risk of GC development without the need for biopsies. Further studies in other populations should be performed to validate the results.

***Non-invasive approaches***

Serum pepsinogen (PG) is the most intensively investigated biomarker for precancerous gastric lesions and GC. Serum PG consists of two distinct types, namely, pepsinogen I (PGI) and pepsinogen II (PGII). PG I is exclusively produced by chief and mucous neck cells in the fundic glands, while PG II is secreted by these cells as well as by cells in the pyloric glands and Brunner’s glands. Both of serum PGI and PGII levels initially increase on the progression of gastritis. However, as the fundic gland mucosa is reduced, PGI levels gradually decrease while PGII levels remain fairly constant. Consequently, the serum PG I/II ratio (sPGr) decreases in a stepwise manner which is closely correlated with the progression of atrophic gastritis[57]. The low serum PG I level and sPGr, therefore, reflect the severity of gastric atrophy. The measurement of serum PG I and sPGr alone or in combination with *H. pylori* serum antibody (HpAb) test, and/or Gastrin-17 has been investigated to identify high-risk individuals[58].

**Non-invasive approaches in western countries:** A study was conducted in 284 dyspeptic patients from 14 European countries to evaluate the role of sPGr as a screening test for moderate-to-severe and multifocal atrophic gastritis[59]. The best cut-off point of sPGr was 5.6, which showed 65.0% sensitivity and 77.9% specificity. Another study, which was one of a few population-based studies in Western countries, was conducted to investigate the serum levels of PGI and sPGr in asymptomatic individuals in northern Portugal, a region with high incidence of GC[60]. The participants, whose ages ranged from 40 to 79 years, were classified into a positive test group (PG I ≤ 70 ng/mL and sPGr ≤ 3) and a negative test group (all others). All participants with a positive test result and a consecutive random sample of participants with negative test results underwent EGD and were followed up in 5 years. In the detection of GC development during the follow-up period, this test showed 67% sensitivity, 47% specificity, a positive predictive value of 2% and a negative predictive value of 99%. Recently, a study investigating the cost-effectiveness of population screening strategies based on biomarkers and endoscopy was conducted in the United States[61]. This study found that although one-time serum PG testing at 50 years of age could prevent one in four cases of GC among men, it was not of high value in improving the outcomes of GC. However, targeting the high-risk group (*i.e.,* male, smokers of > 50 years of age) could be a cost-effective approach for reducing GC-related mortality.

**Non-invasive approaches in eastern countries:** A meta-analysis was conducted to evaluate the prediction of GC development by sPGr, HpAb tests, and a risk-prediction model based on these two tests[62]. This model categorized patients into four groups: low risk (A: HpAb -, sPGr-), moderate risk (B: HpAb+ and sPGr-), and high risk (C: HpAb+ and sPGr+; D: HpAb-and sPGr+). This study included 9 prospective cohorts from Eastern Asian countries with a total of 33741 asymptomatic participants in GC screening programs. The mean ages of the participants at enrollment ranged from 45 to 57 years, while the mean follow-up ranged from 3.9 to 14 years. This study found that adults with a positive sPGr test had an approximately four-fold higher risk of developing GC than those with a negative test. In addition, the four-risk-group prediction model had the potential to stratify middle-aged presumptively healthy adults according to the risk of GC development.

Another meta-analysis, which consisted of over 30000 individuals across 13 different western and eastern countries, was conducted to assess the accuracy of serum PG testing in the diagnosis of GC and chronic atrophic gastritis (CAG)[63]. This study showed that serum PG testing had 69% sensitivity and 73% specificity in the diagnosis of GC, and 69% sensitivity and 88% specificity in the diagnosis of CAG. However, there were significant variations in serum PG measurement methods and cut-off values of PGI and sPGr among the included studies.

One other meta-analysis was conducted to assess the combination of sPGr, gastrin-17 and HpAb tests in the diagnosis of CAG. As Gastrin-17 is only secreted by the G cells of the antral mucosa, a low serum Gastrin-17 level in combination with a positive HpAb test would indicate the presence of antral CAG; and a combination of sPGr, Gastrin-17 and HpAb tests would help to detect the presence and site of CAG[64]. This meta-analysis included 20 eligible studies with a total of 4241 subjects. The median prevalence of CAG across the included studies was 27%. The test sensitivity, specificity, negative predictive value and positive predictive value for the diagnosis of CAG were 74.7%, 95.6%, 91% and 86%, respectively. However, that only six of the 20 included studies considered moderate-to-severe gastric atrophy as a gold standard might have adversely affected the practical usefulness of the study results.

There may be some exceptions regarding the use of the serum PG test in predicting the development of GC in different populations. Notably, a study from Singapore was conducted to examine whether racial differences in the prevalence of *H. pylori* infection and serum PG level could account for racial differences in the incidence of GC[65]. This study found that Indian subjects had a lower incidence of GC but a significantly higher prevalence of low PG in comparison to Chinese and Malay subjects. The study highlighted the limited usefulness of serum PG testing in the Indian population. In addition, the rPGr level has been recently reported to return to the normal range in Japanese patients after successful *H. pylori* eradication[66]. Thus, test results may be misleading in populations in which a large percentage of participants have undergone *H. pylori* eradication (intended and unintended).

**LESSONS FROM WESTERN AND EASTERN PERSPECTIVES AND THE POSSIBILITY OF DEVELOPING AN INTEGRATED RESOURCE-SENSITIVE APPROACH TO IDENTIFY HIGH-RISK INDIVIDUALS**

***Pre-endoscopic risk assessment***

The detection of high-risk precancerous gastric lesions generally requires endoscopy with biopsy. However, there are demographic and clinical features that are helpful for predicting the presence of these lesions, including ethnicity, gender, age, family history of GC, *H. pylori* status and serum PG level[4,50,67,68].

A recent review found that individuals in the United States who are immigrants from high-risk regions (East Asia, Russia, or South America) had a higher risk of GC development in comparison to other Americans[68]. In multi-ethnic Southeast Asia countries, it was reported that some ethnic groups, including Chinese, Batak and Minahasanese, had higher risk in comparison to the other ethnic groups[4]. *H. pylori* infection and having first-degree relatives diagnosed with GC have been reported as important risk factors for GC development worldwide[8,67,68]. In addition, male sex, smoking and advanced age are also associated with a higher risk of developing GC[61,69,70]. The age threshold may differ depending on the GC risk level in each region: it is approximately 40 years in high-risk regions and approximately 50 years in low-risk regions[67-69]. In subjects with family history of GC, the age threshold is approximately 10 years younger than the age of the ﬁrst-degree relative at the diagnosis or 50 years of age (whichever is earlier)[68]. The application of the PG test in subjects with clinical high-risk characteristics has been shown to be promising but, as mentioned above, should be locally validated.

In summary, pre-endoscopic risk assessment is possible and it is helpful for selecting subjects with a high pre-test probability for a possibly cost-effective approach, especially in intermediate- and low-risk regions.

***Approaches for asymptomatic individuals***

The two key issues in selecting applicable approaches for asymptomatic individuals are the ability to reduce GC mortality, especially in high-risk regions, and the cost-effectiveness of the approach, especially in low- and intermediate-risk regions. The possibly applicable approaches, based on current evidence worldwide are summarized in Figure 2.

**Approaches for asymptomatic individuals in eastern countries:** At present, population-based screening programs have only been applied in some Asian countries with a high incidence of GC. In South Korea, the national cancer screening program for GC by EGD or upper gastrointestinal series (UGS) was launched in 1999 as a Medicaid program, but it has since expanded to all subjects of ≥ 40 years of age since 2005[71]. A recent nested case-control study was conducted to assess the effectiveness of this program in reducing GC mortality. The study used data from 16584283 subjects who participated in the screening program since 2002, and found that the subjects who received EGD were less likely to die from GC in comparison to those who received UGS[72]. In Japan, a recent cohort study reported that the survival rate and GC mortality among Japanese patients with screening-detected GC were not significantly different from those with interval GC in the annual endoscopic screening program, which also suggested the benefit of endoscopic screening in reducing GC mortality[73]. The current Japanese guidelines for GC screening recommend the use of EGD or UGS for population-based and opportunistic screenings, but emphasize that the former method is more sensitive than the later[74]. Serum PG and HpAb tests are currently not recommended for population-based screening in Japan due to insufficient evidence on the reduction of GC mortality. In China, there have been no national screening programs for GC but some screening programs have been applied in high-risk regions of the country. Among these programs, the so-called two-step examination (*i.e.,* the sequential sPGr-EGD screening method) has been reported to have reasonable cost-effectiveness and good participant compliance[5]. A recent meta-analysis and systematic review, which included 6 cohort studies and 4 nested case-control studies from high-risk Asian countries (2 from South Korea, 2 from China, and 6 from Japan) with 342013 individuals, has been conducted to investigate how endoscopic screening affected the incidence of GC or GC mortality. This study found that endoscopic screening may reduce GC mortality, regardless of the incidence of GC in the included populations. The subgroup analysis showed signiﬁcant reductions in GC mortality after endoscopic screening in comparison to no screening[75].

In other Asian countries, there have been no national screening programs. We recently conducted a survey about the management of *H. pylori* and GC across 9 South-East Asian countries[4], and found that most lesions were diagnosed in an advanced stage and that the prognosis of GC patients was very poor. Resource limitations are among the most challenging issues for countries with limited resources but a high prevalence of GC. In Singapore’s multi-ethnic population, the risk in Chinese is higher in comparison to Malaysians and Indians. A cost utility analysis was conducted to determine whether endoscopic screening for GC would be cost-effective and to better define the high-risk group[69]. This study found that screening of the high-risk group of Chinese men (age-standardized rate, 25.9/100000) from 50-70 years of age is highly cost-effective.

**Approaches for asymptomatic individuals in western countries:** Most western countries have low or intermediate GC risk (Figure 3). Thus, cost-effectiveness is the main issue concerning the selection of a suitable approach.

The longest follow-up study using serum PG screening tests for GC detection in the West was conducted in the northern part of Portugal, the area with the highest incidence of GC in Western Europe[76]. This cohort included 5913 individuals, of 40-74 years of age, who were subjected to the PG test (PGI = 70 ng/mL and sPGr ≥ 3). This study found that the PG test was suboptimal as a screening test for GC as its sensitivity was only 35% at the initial stage and 58% after 3 years of follow-up.

National screening programs for colon cancer have been well-developed in many western countries. Thus, in this region, there have been intensive investigations to determine a reasonable approach for combining gastric and colorectal cancer screening.

An analysis using a Markov model to determine the cost-utility of screening strategies for GC in Portugal was recently reported[77]. The three following screening strategies were compared vs no screening: stand-alone EGD, EGD combined with a colorectal cancer screening colonoscopy after a positive fecal occult blood test or a positive serum PG test. This study found that endoscopic GC screening in Europe could be cost-effective if combined with screening colonoscopy in countries with an age-standardized rate (ASR) of ≥ 10 per 100000. Based on the cost of EGD alone (< €75), the provision of only three EGDs per patient or an ASR > 25/100000 would make stand-alone endoscopic screening cost-effective. Interestingly, this analysis of cost efficacy also supports the national endoscopic screening programs that are currently running in Japan and South Korea (ASR 27.5 and 39.6 per 100.000, respectively)[1].

The marked differences in the prevalence of GC among different ethnic groups in multi-ethnic countries may also affect the cost-effectiveness of the approach. In the United States, a recent study investigated whether selected non-cardia GC screening for members of high-risk ethnic groups was cost-effective[70]. A decision analytic Markov model was developed with the base case of a 50-year-old person of non-Hispanic white, non-Hispanic black, Hispanic, or Asian ethnicity. The cost effectiveness of a no-screening strategy (current standard) for non-cardia GC was compared with that of two endoscopic screening modalities initiated at the time of screening colonoscopy for colorectal cancer: EGD with biopsy examinations and continued surveillance, only if GIM or more severe histological findings are identiﬁed, or EGD with biopsy examinations continued every 2 years even in the absence of these histological findings. Compared with biennial and no screening, EGD screening with continued surveillance only when indicated was cost effective for non-Hispanic blacks, Hispanics, and Asians, but not for non-Hispanic whites. The cost-effectiveness was highest for Asians. A selective screening approach based on ethnicity, family history of GC and the age threshold has also been recently proposed in the United States[68].

***Approaches for patients who have indications for EGD according to the current guidelines***

Definitely, symptomatic patients who have indications for EGD according to the current guidelines for upper gastrointestinal symptoms are the subjects who benefit the most from opportunistic screening, regardless of the GC risk levels in their countries. However, we believe that the importance of opportunistic screening should be further emphasized in guidelines for dyspepsia and gastroesophageal reflux disease management and should always be considered whenever EGD is performed.

The combination of endoscopic and histological approaches should always be considered as it has several advantages. First, endoscopy provides a real-time assessment of the patient’s risk of GC development. As endoscopists tend to focus on endoscopic findings that explain patient symptoms, it is important to be cautious that precancerous gastric lesions and even early GCs may already exist. These subtle lesions are often not the causes of the symptom(s) and are very easy to miss[5]. Second, the results of histological examination greatly depend on the location from which the specimens are taken. New endoscopic technologies have helped to improve the endoscopist’s ability to identify subtle changes in the gastric mucosa and facilitate targeted biopsies instead of mapping biopsies, which results in a better correlation between endoscopic and histological findings[50,52,55,56].

How to make this combined approach widely applicable in daily practice is a crucial issue. Obviously, an ideal approach should be accurate as well as feasible; it should not be time-consuming or require special expertise or equipment. Currently, the best evidence supports the use of IEE for endoscopy and OLGIM/OLGA grading systems for histological examination whenever applicable. However, resource limitations are an important barrier in many regions worldwide. Notably, there are several countries with a high risk of GC but limited resources, including Mongolia and Vietnam[1]. Resources may also be quite different within the same country, was as reported in our recent survey of 9 Southeast Asian countries[78]. Thus, a suitable approach should not only be evidence-based but also resource-sensitive (Figure 4).

**Endoscopic strategy:** Regions with high resources: Start with WLE and escalate to IEE if necessary. Recent studies from the east and west strongly support that IEE, in addition to WLE, improves the rate at which gastric premalignant mucosal changes such as gastric atrophy and GIM are endoscopically detected[50,55,56].

Regions with limited resources (IEE is unavailable): Start with WLE and evaluate the severity of EGA. Recently, several cohort studies in Asia have shown that EAG assessment can help to effectively identify high-risk individuals with a higher risk of GC development among patients with moderate-to-severe EGA[8,34,45]. A recent global consensus on gastritis recommends that EGA be used if expert endoscopists are available[10]. We previously reported good to excellent intraobserver agreement and a moderate interobserver agreement among experienced endoscopists in the assessment of the severity of EGA[79]. A recent study reported that the interobserver agreement for the diagnosis and grading of EGA significantly improved after proper training and that it remained stable after intervention, irrespective of the endoscopist’s experience level[80]. Thus, this endoscopic assessment, which requires no additional equipment, is potentially useful in regions with limited resources. One limitation of EGA assessment that should be kept in mind is that the improvement of the severity of EGA may not be parallel with histological gastric atrophy after successful *H. pylori* eradication[81]. In such situations, it is necessary to obtain biopsy specimens for histological examination, especially if the baseline histological results are not available.

**Biopsy strategy:** Obviously, endoscopically visible gastric lesions that are suspected to represent precancerous gastric lesions and GC should be biopsied. However, the strategy of taking mapping biopsies may differ depending on the local resources (Figure 4).

In regions with high resources, the performance of a mapping biopsy at mucosal sites is recommended, according to the Sydney protocol, for patients with endoscopic findings suggestive of chronic gastritis[10]. A biopsy specimen from the angularis angular is essential in order not to downgrade the OLGA and OLGIM gastritis stage and miss high-risk individuals[82]. Specimens from each site should be put into separate container. Whenever available, IEE should be used for detection and obtaining targeted biopsy specimens[50]. Regarding histological assessment, the OLGIM and OLGA staging systems should be applied[9,10]. However, a recent South Korean study found that only about one quarter of GC patients in this high-risk population had high-stage OLGA and OLGIM gastritis. Thus, the sensitivity of these staging systems as indicators for GC in Asians, may be lower in comparison to the sensitivity reported in western populations, and local validation is required[83]. A GIM subtype analysis may be considered but is not a necessity, as the presence of incomplete GIM is significantly associated with extensive GIM, which is a documented marker that is easier to evaluate[32,33,84].

In regions with limited resources, mapping biopsy is also recommended and specimens from each site should be put into separate containers as mentioned above. In some developing countries, the cost of histological examinations is not currently reimbursed and the cost increment of additional containers may not be affordable for many self-paid patients[4]. As patients with extensive gastric atrophy and/or GIM have a higher risk of GC development[32,34,35], a reasonable option is to take 5 biopsies at mucosal sites according to the Sydney protocol and put them into 2 separate containers for the antrum and the corpus. Another option is to define high-risk patients based on EGA severity alone, if well-trained endoscopists are available.

***Approach for patients with upper gastrointestinal symptoms who do not yet have indications for EGD according to the current guidelines***

The indications for EGD according to the current guidelines on dyspepsia or gastroesophageal reflux disease are mainly to detect organic diseases that cause the patient’s symptoms, especially to rule out upper gastrointestinal malignancies. For a long time, the role of EGD as an opportunistic screening tool for these malignancies, including GC, has not been sufficiently emphasized. In our opinion, the benefits from opportunistic screening by EGD should also be considered whenever we decide whether patients with upper gastrointestinal symptoms should undergo EGD. There is currently no evidence on this topic and it represents an important and interesting direction for future research.

**CONCLUSION**

The characteristics of individuals with high risk for GC development are well recognized. There are several strategies that employ non-invasive, endoscopic, histological or combined approaches in order to attempt to identify these individuals. The main approach in western countries is histology-based while that in eastern countries with high prevalence of GC is endoscopy-based. Although some approaches have demonstrated their cost effectiveness and their ability to reduce GC mortality, these cannot be widely applied in many regions due to resource limitations. Based on the current evidence from both western and eastern perspectives, an integrated and resource-sensitive approach could be developed for real-life practice.

**REFERENCES**

1 Globocan. Available from: https://gco.iarc.fr/.2018

2 **Fuchs CS**, Mayer RJ. Gastric carcinoma. *N Engl J Med* 1995; **333**: 32-41 [PMID: 7776992 DOI: 10.1056/NEJM199507063330107]

3 **Bai Y**, Li ZS, Zou DW, Wu RP, Yao YZ, Jin ZD, Ye P, Li SD, Zhang WJ, Du YQ, Zhan XB, Liu F, Gao J, Xu GM. Alarm features and age for predicting upper gastrointestinal malignancy in Chinese patients with dyspepsia with high background prevalence of Helicobacter pylori infection and upper gastrointestinal malignancy: an endoscopic database review of 102,665 patients from 1996 to 2006. *Gut* 2010; **59**: 722-728 [PMID: 20551455 DOI: 10.1136/gut.2009.192401]

4 **Quach DT**, Vilaichone RK, Vu KV, Yamaoka Y, Sugano K, Mahachai V. Helicobacter pylori Infection and Related Gastrointestinal Diseases in Southeast Asian Countries: An Expert Opinion Survey *Asian Pac J Cancer Prev* 2018; **19**: 3565-3569 [PMID: 30583684 DOI: 10.31557/APJCP.2018.19.12.3565]

5 **Yuan Y**. A survey and evaluation of population-based screening for gastric cancer. *Cancer Biol Med* 2013; **10**: 72-80 [PMID: 23882421 DOI: 10.7497/j.issn.2095-3941.2013.02.002]

6 **Correa P**, Piazuelo MB. The gastric precancerous cascade. *J Dig Dis* 2012; **13**: 2-9 [PMID: 22188910 DOI: 10.1111/j.1751-2980.2011.00550.x]

7 **Tsukuma H**, Oshima A, Narahara H, Morii T. Natural history of early gastric cancer: a non-concurrent, long term, follow up study. *Gut* 2000; **47**: 618-621 [PMID: 11034575]

8 **Uemura N**, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ. Helicobacter pylori infection and the development of gastric cancer. *N Engl J Med* 2001; **345**: 784-789 [PMID: 11556297 DOI: 10.1056/NEJMoa001999]

9 **Dinis-Ribeiro M**, Areia M, de Vries AC, Marcos-Pinto R, Monteiro-Soares M, O'Connor A, Pereira C, Pimentel-Nunes P, Correia R, Ensari A, Dumonceau JM, Machado JC, Macedo G, Malfertheiner P, Matysiak-Budnik T, Megraud F, Miki K, O'Morain C, Peek RM, Ponchon T, Ristimaki A, Rembacken B, Carneiro F, Kuipers EJ; European Society of Gastrointestinal Endoscopy; European Helicobacter Study Group; European Society of Pathology; Sociedade Portuguesa de Endoscopia Digestiva. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). *Endoscopy* 2012; **44**: 74-94 [PMID: 22198778 DOI: 10.1055/s-0031-1291491]

10 **Sugano K**, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, Haruma K, Asaka M, Uemura N, Malfertheiner P; faculty members of Kyoto Global Consensus Conference. Kyoto global consensus report on Helicobacter pylori gastritis. *Gut* 2015; **64**: 1353-1367 [PMID: 26187502 DOI: 10.1136/gutjnl-2015-309252]

11 **Sung JK**. Diagnosis and management of gastric dysplasia. *Korean J Intern Med* 2016; **31**: 201-209 [PMID: 26932397 DOI: 10.3904/kjim.2016.021]

12 **Yue H**, Shan L, Bin L. The significance of OLGA and OLGIM staging systems in the risk assessment of gastric cancer: a systematic review and meta-analysis. *Gastric Cancer* 2018; **21**: 579-587 [PMID: 29460004 DOI: 10.1007/s10120-018-0812-3]

13 **Chen HN**, Wang Z, Li X, Zhou ZG. Helicobacter pylori eradication cannot reduce the risk of gastric cancer in patients with intestinal metaplasia and dysplasia: evidence from a meta-analysis. *Gastric Cancer* 2016; **19**: 166-175 [PMID: 25609452 DOI: 10.1007/s10120-015-0462-7]

14 **Spence AD**, Cardwell CR, McMenamin ÚC, Hicks BM, Johnston BT, Murray LJ, Coleman HG. Adenocarcinoma risk in gastric atrophy and intestinal metaplasia: a systematic review. *BMC Gastroenterol* 2017; **17**: 157 [PMID: 29228909 DOI: 10.1186/s12876-017-0708-4]

15 **Correa P**. Chronic gastritis: a clinico-pathological classification. *Am J Gastroenterol* 1988; **83**: 504-509 [PMID: 3364410]

16 **Andrew A**, Wyatt JI, Dixon MF. Observer variation in the assessment of chronic gastritis according to the Sydney system. *Histopathology* 1994; **25**: 317-322 [PMID: 7835836]

17 **Rugge M**, Correa P, Dixon MF, Fiocca R, Hattori T, Lechago J, Leandro G, Price AB, Sipponen P, Solcia E, Watanabe H, Genta RM. Gastric mucosal atrophy: interobserver consistency using new criteria for classification and grading. *Aliment Pharmacol Ther* 2002; **16**: 1249-1259 [PMID: 12144574]

18 **Rugge M**, Genta RM; OLGA Group. Staging gastritis: an international proposal. *Gastroenterology* 2005; **129**: 1807-1808 [PMID: 16285989 DOI: 10.1053/j.gastro.2005.09.056]

19 **Rugge M**, Correa P, Di Mario F, El-Omar E, Fiocca R, Geboes K, Genta RM, Graham DY, Hattori T, Malfertheiner P, Nakajima S, Sipponen P, Sung J, Weinstein W, Vieth M. OLGA staging for gastritis: a tutorial. *Dig Liver Dis* 2008; **40**: 650-658 [PMID: 18424244 DOI: 10.1016/j.dld.2008.02.030]

20 **Rugge M**, Kim JG, Mahachai V, Miehlke S, Pennelli G, Russo VM, Perng CL, Chang FY, Tandon RK, Singal DK, Sung JJ, Valenzuela JE, Realdi G, Dore MP, Graham DY. OLGA gastritis staging in young adults and country-specific gastric cancer risk. *Int J Surg Pathol* 2008; **16**: 150-154 [PMID: 18417671 DOI: 10.1177/1066896907307238]

21 **Rugge M**, Meggio A, Pennelli G, Piscioli F, Giacomelli L, De Pretis G, Graham DY. Gastritis staging in clinical practice: the OLGA staging system. *Gut* 2007; **56**: 631-636 [PMID: 17142647 DOI: 10.1136/gut.2006.106666]

22 **Quach DT**, Le HM, Nguyen OT, Nguyen TS, Uemura N. The severity of endoscopic gastric atrophy could help to predict Operative Link on Gastritis Assessment gastritis stage. *J Gastroenterol Hepatol* 2011; **26**: 281-285 [PMID: 21261717 DOI: 10.1111/j.1440-1746.2010.06474.x]

23 **Rugge M**, Genta RM, Fassan M, Valentini E, Coati I, Guzzinati S, Savarino E, Zorzi M, Farinati F, Malfertheiner P. OLGA Gastritis Staging for the Prediction of Gastric Cancer Risk: A Long-term Follow-up Study of 7436 Patients. *Am J Gastroenterol* 2018; **113**: 1621-1628 [PMID: 30333540 DOI: 10.1038/s41395-018-0353-8]

24 **Rugge M**, Meggio A, Pravadelli C, Barbareschi M, Fassan M, Gentilini M, Zorzi M, Pretis G, Graham DY, Genta RM. Gastritis staging in the endoscopic follow-up for the secondary prevention of gastric cancer: a 5-year prospective study of 1755 patients. *Gut* 2019; **68**: 11-17 [PMID: 29306868 DOI: 10.1136/gutjnl-2017-314600]

25 **de Vries AC**, Kuipers EJ. Epidemiology of premalignant gastric lesions: implications for the development of screening and surveillance strategies. *Helicobacter* 2007; **12 Suppl 2**: 22-31 [PMID: 17991173 DOI: 10.1111/j.1523-5378.2007.00562.x]

26 **Song H**, Ekheden IG, Zheng Z, Ericsson J, Nyrén O, Ye W. Incidence of gastric cancer among patients with gastric precancerous lesions: observational cohort study in a low risk Western population. *BMJ* 2015; **351**: h3867 [PMID: 26215280 DOI: 10.1136/bmj.h3867]

27 **Filipe MI**, Muñoz N, Matko I, Kato I, Pompe-Kirn V, Jutersek A, Teuchmann S, Benz M, Prijon T. Intestinal metaplasia types and the risk of gastric cancer: a cohort study in Slovenia. *Int J Cancer* 1994; **57**: 324-329 [PMID: 8168991]

28 **González CA**, Pardo ML, Liso JM, Alonso P, Bonet C, Garcia RM, Sala N, Capella G, Sanz-Anquela JM. Gastric cancer occurrence in preneoplastic lesions: a long-term follow-up in a high-risk area in Spain. *Int J Cancer* 2010; **127**: 2654-2660 [PMID: 20178099 DOI: 10.1002/ijc.25273]

29 **Kang KP**, Lee HS, Kim N, Kang HM, Park YS, Lee DH, Choe G, Kim JS, Jung HC, Song IS. Role of intestinal metaplasia subtyping in the risk of gastric cancer in Korea. *J Gastroenterol Hepatol* 2009; **24**: 140-148 [PMID: 18713298 DOI: 10.1111/j.1440-1746.2008.05546.x]

30 **González CA**, Sanz-Anquela JM, Gisbert JP, Correa P. Utility of subtyping intestinal metaplasia as marker of gastric cancer risk. A review of the evidence. *Int J Cancer* 2013; **133**: 1023-1032 [PMID: 23280711 DOI: 10.1002/ijc.28003]

31 **Pittayanon R**, Rerknimitr R, Klaikaew N, Sanpavat A, Chaithongrat S, Mahachai V, Kullavanijaya P, Barkun A. The risk of gastric cancer in patients with gastric intestinal metaplasia in 5-year follow-up. *Aliment Pharmacol Ther* 2017; **46**: 40-45 [PMID: 28449219 DOI: 10.1111/apt.14082]

32 **Cassaro M**, Rugge M, Gutierrez O, Leandro G, Graham DY, Genta RM. Topographic patterns of intestinal metaplasia and gastric cancer. *Am J Gastroenterol* 2000; **95**: 1431-1438 [PMID: 10894575 DOI: 10.1111/j.1572-0241.2000.02074.x]

33 **Tava F**, Luinetti O, Ghigna MR, Alvisi C, Perego M, Trespi E, Klersy C, Fratti C, Fiocca R, Solcia E. Type or extension of intestinal metaplasia and immature/atypical "indefinite-for-dysplasia" lesions as predictors of gastric neoplasia. *Hum Pathol* 2006; **37**: 1489-1497 [PMID: 16949645 DOI: 10.1016/j.humpath.2006.05.012]

34 **Shichijo S**, Hirata Y, Niikura R, Hayakawa Y, Yamada A, Ushiku T, Fukayama M, Koike K. Histologic intestinal metaplasia and endoscopic atrophy are predictors of gastric cancer development after Helicobacter pylori eradication. *Gastrointest Endosc* 2016; **84**: 618-624 [PMID: 26995689 DOI: 10.1016/j.gie.2016.03.791]

35 **Capelle LG**, de Vries AC, Haringsma J, Ter Borg F, de Vries RA, Bruno MJ, van Dekken H, Meijer J, van Grieken NC, Kuipers EJ. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. *Gastrointest Endosc* 2010; **71**: 1150-1158 [PMID: 20381801 DOI: 10.1016/j.gie.2009.12.029]

36 **el-Zimaity HM**, Graham DY, al-Assi MT, Malaty H, Karttunen TJ, Graham DP, Huberman RM, Genta RM. Interobserver variation in the histopathological assessment of Helicobacter pylori gastritis. *Hum Pathol* 1996; **27**: 35-41 [PMID: 8543308]

37 **Chen XY**, van der Hulst RW, Bruno MJ, van der Ende A, Xiao SD, Tytgat GN, Ten Kate FJ. Interobserver variation in the histopathological scoring of Helicobacter pylori related gastritis. *J Clin Pathol* 1999; **52**: 612-615 [PMID: 10645232]

38 **Dixon MF**. Gastrointestinal epithelial neoplasia: Vienna revisited. *Gut* 2002; **51**: 130-131 [PMID: 12077106]

39 **de Vries AC**, van Grieken NC, Looman CW, Casparie MK, de Vries E, Meijer GA, Kuipers EJ. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. *Gastroenterology* 2008; **134**: 945-952 [PMID: 18395075 DOI: 10.1053/j.gastro.2008.01.071]

40 **Maekawa A**, Kato M, Nakamura T, Komori M, Yamada T, Yamamoto K, Ogiyama H, Nakahara M, Kawai N, Yabuta T, Mukai A, Hayashi Y, Nishida T, Iijima H, Tsujii M, Morii E, Takehara T. Incidence of gastric adenocarcinoma among lesions diagnosed as low-grade adenoma/dysplasia on endoscopic biopsy: A multicenter, prospective, observational study. *Dig Endosc* 2018; **30**: 228-235 [PMID: 29094455 DOI: 10.1111/den.12980]

41 **ASGE Standards of Practice Committee**, Evans JA, Chandrasekhara V, Chathadi KV, Decker GA, Early DS, Fisher DA, Foley K, Hwang JH, Jue TL, Lightdale JR, Pasha SF, Sharaf R, Shergill AK, Cash BD, DeWitt JM. The role of endoscopy in the management of premalignant and malignant conditions of the stomach. *Gastrointest Endosc* 2015; **82**: 1-8 [PMID: 25935705 DOI: 10.1016/j.gie.2015.03.1967]

42 **Kokkola A**, Haapiainen R, Laxén F, Puolakkainen P, Kivilaakso E, Virtamo J, Sipponen P. Risk of gastric carcinoma in patients with mucosal dysplasia associated with atrophic gastritis: a follow up study. *J Clin Pathol* 1996; **49**: 979-984 [PMID: 9038734]

43 **Eshmuratov A**, Nah JC, Kim N, Lee HS, Lee HE, Lee BH, Uhm MS, Park YS, Lee DH, Jung HC, Song IS. The correlation of endoscopic and histological diagnosis of gastric atrophy. *Dig Dis Sci* 2010; **55**: 1364-1375 [PMID: 19629687 DOI: 10.1007/s10620-009-0891-4]

44 **Kono S**, Gotoda T, Yoshida S, Oda I, Kondo H, Gatta L, Naylor G, Dixon M, Moriyasu F, Axon A. Can endoscopic atrophy predict histological atrophy? Historical study in United Kingdom and Japan. *World J Gastroenterol* 2015; **21**: 13113-13123 [PMID: 26673849 DOI: 10.3748/wjg.v21.i46.13113]

45 **Take S**, Mizuno M, Ishiki K, Yoshida T, Ohara N, Yokota K, Oguma K, Okada H, Yamamoto K. The long-term risk of gastric cancer after the successful eradication of Helicobacter pylori. *J Gastroenterol* 2011; **46**: 318-324 [PMID: 21103997 DOI: 10.1007/s00535-010-0347-9]

46 **Kimura K**, Takemoto T. An Endoscopic Recognition of the Atrophic Border and its Significance in Chronic Gastritis. *Endoscopy* 2008; **1**: 87-97 [DOI: 10.1055/s-0028-1098086]

47 **Lim JH**, Kim N, Lee HS, Choe G, Jo SY, Chon I, Choi C, Yoon H, Shin CM, Park YS, Lee DH, Jung HC. Correlation between Endoscopic and Histological Diagnoses of Gastric Intestinal Metaplasia. *Gut Liver* 2013; **7**: 41-50 [PMID: 23423616 DOI: 10.5009/gnl.2013.7.1.41]

48 **Panteris V**, Nikolopoulou S, Lountou A, Triantafillidis JK. Diagnostic capabilities of high-definition white light endoscopy for the diagnosis of gastric intestinal metaplasia and correlation with histologic and clinical data. *Eur J Gastroenterol Hepatol* 2014; **26**: 594-601 [PMID: 24743505 DOI: 10.1097/MEG.0000000000000097]

49 **Ang TL**, Pittayanon R, Lau JY, Rerknimitr R, Ho SH, Singh R, Kwek AB, Ang DS, Chiu PW, Luk S, Goh KL, Ong JP, Tan JY, Teo EK, Fock KM. A multicenter randomized comparison between high-definition white light endoscopy and narrow band imaging for detection of gastric lesions. *Eur J Gastroenterol Hepatol* 2015; **27**: 1473-1478 [PMID: 26426836 DOI: 10.1097/MEG.0000000000000478]

50 **Chiu PWY**, Uedo N, Singh R, Gotoda T, Ng EKW, Yao K, Ang TL, Ho SH, Kikuchi D, Yao F, Pittayanon R, Goda K, Lau JYW, Tajiri H, Inoue H. An Asian consensus on standards of diagnostic upper endoscopy for neoplasia. *Gut* 2019; **68**: 186-197 [PMID: 30420400 DOI: 10.1136/gutjnl-2018-317111]

51 **Uedo N**, Ishihara R, Iishi H, Yamamoto S, Yamamoto S, Yamada T, Imanaka K, Takeuchi Y, Higashino K, Ishiguro S, Tatsuta M. A new method of diagnosing gastric intestinal metaplasia: narrow-band imaging with magnifying endoscopy. *Endoscopy* 2006; **38**: 819-824 [PMID: 17001572 DOI: 10.1055/s-2006-944632]

52 **Wang L**, Huang W, Du J, Chen Y, Yang J. Diagnostic yield of the light blue crest sign in gastric intestinal metaplasia: a meta-analysis. *PLoS One* 2014; **9**: e92874 [PMID: 24658503 DOI: 10.1371/journal.pone.0092874]

53 **Saka A**, Yagi K, Nimura S. OLGA- and OLGIM-based staging of gastritis using narrow-band imaging magnifying endoscopy. *Dig Endosc* 2015; **27**: 734-741 [PMID: 25923666 DOI: 10.1111/den.12483]

54 **Pimentel-Nunes P**, Dinis-Ribeiro M, Soares JB, Marcos-Pinto R, Santos C, Rolanda C, Bastos RP, Areia M, Afonso L, Bergman J, Sharma P, Gotoda T, Henrique R, Moreira-Dias L. A multicenter validation of an endoscopic classification with narrow band imaging for gastric precancerous and cancerous lesions. *Endoscopy* 2012; **44**: 236-246 [PMID: 22294194 DOI: 10.1055/s-0031-1291537]

55 **Pimentel-Nunes P**, Libânio D, Lage J, Abrantes D, Coimbra M, Esposito G, Hormozdi D, Pepper M, Drasovean S, White JR, Dobru D, Buxbaum J, Ragunath K, Annibale B, Dinis-Ribeiro M. A multicenter prospective study of the real-time use of narrow-band imaging in the diagnosis of premalignant gastric conditions and lesions. *Endoscopy* 2016; **48**: 723-730 [PMID: 27280384 DOI: 10.1055/s-0042-108435]

56 **Esposito G**, Pimentel-Nunes P, Angeletti S, Castro R, Libânio D, Galli G, Lahner E, Di Giulio E, Annibale B, Dinis-Ribeiro M. Endoscopic grading of gastric intestinal metaplasia (EGGIM): a multicenter validation study. *Endoscopy* 2019; **51**: 515-521 [PMID: 30577062 DOI: 10.1055/a-0808-3186]

57 **Miki K**. Gastric cancer screening using the serum pepsinogen test method. *Gastric Cancer* 2006; **9**: 245-253 [PMID: 17235625 DOI: 10.1007/s10120-006-0397-0]

58 **Zagari RM**, Rabitti S, Greenwood DC, Eusebi LH, Vestito A, Bazzoli F. Systematic review with meta-analysis: diagnostic performance of the combination of pepsinogen, gastrin-17 and anti-Helicobacter pylori antibodies serum assays for the diagnosis of atrophic gastritis. *Aliment Pharmacol Ther* 2017; **46**: 657-667 [PMID: 28782119 DOI: 10.1111/apt.14248]

59 **Broutet N**, Plebani M, Sakarovitch C, Sipponen P, Mégraud F; Eurohepygast Study Group. Pepsinogen A, pepsinogen C, and gastrin as markers of atrophic chronic gastritis in European dyspeptics. *Br J Cancer* 2003; **88**: 1239-1247 [PMID: 12698190 DOI: 10.1038/sj.bjc.6600877]

60 **Lomba-Viana R**, Dinis-Ribeiro M, Fonseca F, Vieira AS, Bento MJ, Lomba-Viana H. Serum pepsinogen test for early detection of gastric cancer in a European country. *Eur J Gastroenterol Hepatol* 2012; **24**: 37-41 [PMID: 21989121 DOI: 10.1097/MEG.0b013e32834d0a0a]

61 **Yeh JM**, Hur C, Ward Z, Schrag D, Goldie SJ. Gastric adenocarcinoma screening and prevention in the era of new biomarker and endoscopic technologies: a cost-effectiveness analysis. *Gut* 2016; **65**: 563-574 [PMID: 25779597 DOI: 10.1136/gutjnl-2014-308588]

62 **Terasawa T**, Nishida H, Kato K, Miyashiro I, Yoshikawa T, Takaku R, Hamashima C. Prediction of gastric cancer development by serum pepsinogen test and Helicobacter pylori seropositivity in Eastern Asians: a systematic review and meta-analysis. *PLoS One* 2014; **9**: e109783 [PMID: 25314140 DOI: 10.1371/journal.pone.0109783]

63 **Huang YK**, Yu JC, Kang WM, Ma ZQ, Ye X, Tian SB, Yan C. Significance of Serum Pepsinogens as a Biomarker for Gastric Cancer and Atrophic Gastritis Screening: A Systematic Review and Meta-Analysis. *PLoS One* 2015; **10**: e0142080 [PMID: 26556485 DOI: 10.1371/journal.pone.0142080]

64 **Agréus L**, Kuipers EJ, Kupcinskas L, Malfertheiner P, Di Mario F, Leja M, Mahachai V, Yaron N, van Oijen M, Perez Perez G, Rugge M, Ronkainen J, Salaspuro M, Sipponen P, Sugano K, Sung J. Rationale in diagnosis and screening of atrophic gastritis with stomach-specific plasma biomarkers. *Scand J Gastroenterol* 2012; **47**: 136-147 [PMID: 22242613 DOI: 10.3109/00365521.2011.645501]

65 **Ang TL**, Fock KM, Dhamodaran S, Teo EK, Tan J. Racial differences in Helicobacter pylori, serum pepsinogen and gastric cancer incidence in an urban Asian population. *J Gastroenterol Hepatol* 2005; **20**: 1603-1609 [PMID: 16174081 DOI: 10.1111/j.1440-1746.2005.03898.x]

66 **Osumi H**, Fujisaki J, Suganuma T, Horiuchi Y, Omae M, Yoshio T, Ishiyama A, Tsuchida T, Miki K. A significant increase in the pepsinogen I/II ratio is a reliable biomarker for successful Helicobacter pylori eradication. *PLoS One* 2017; **12**: e0183980 [PMID: 28854276 DOI: 10.1371/journal.pone.0183980]

67 **Fock KM**, Talley N, Moayyedi P, Hunt R, Azuma T, Sugano K, Xiao SD, Lam SK, Goh KL, Chiba T, Uemura N, Kim JG, Kim N, Ang TL, Mahachai V, Mitchell H, Rani AA, Liou JM, Vilaichone RK, Sollano J; Asia-Pacific Gastric Cancer Consensus Conference. Asia-Pacific consensus guidelines on gastric cancer prevention. *J Gastroenterol Hepatol* 2008; **23**: 351-365 [PMID: 18318820 DOI: 10.1111/j.1440-1746.2008.05314.x]

68 **Kim GH**, Liang PS, Bang SJ, Hwang JH. Screening and surveillance for gastric cancer in the United States: Is it needed? *Gastrointest Endosc* 2016; **84**: 18-28 [PMID: 26940296 DOI: 10.1016/j.gie.2016.02.028]

69 **Dan YY**, So JB, Yeoh KG. Endoscopic screening for gastric cancer. *Clin Gastroenterol Hepatol* 2006; **4**: 709-716 [PMID: 16765306 DOI: 10.1016/j.cgh.2006.03.025]

70 **Saumoy M**, Schneider Y, Shen N, Kahaleh M, Sharaiha RZ, Shah SC. Cost Effectiveness of Gastric Cancer Screening According to Race and Ethnicity. *Gastroenterology* 2018; **155**: 648-660 [PMID: 29778607 DOI: 10.1053/j.gastro.2018.05.026]

71 **Choi IJ**. Endoscopic gastric cancer screening and surveillance in high-risk groups. *Clin Endosc* 2014; **47**: 497-503 [PMID: 25505714 DOI: 10.5946/ce.2014.47.6.497]

72 **Jun JK**, Choi KS, Lee HY, Suh M, Park B, Song SH, Jung KW, Lee CW, Choi IJ, Park EC, Lee D. Effectiveness of the Korean National Cancer Screening Program in Reducing Gastric Cancer Mortality. *Gastroenterology* 2017; **152**: 1319-1328.e7 [PMID: 28147224 DOI: 10.1053/j.gastro.2017.01.029]

73 **Hamashima C**, Shabana M, Okamoto M, Osaki Y, Kishimoto T. Survival analysis of patients with interval cancer undergoing gastric cancer screening by endoscopy. *PLoS One*2015; **10**: e0126796 [PMID: 26023768 DOI: 10.1371/journal.pone.0126796]

74 **Hamashima C**; Systematic Review Group and Guideline Development Group for Gastric Cancer Screening Guidelines. Update version of the Japanese Guidelines for Gastric Cancer Screening. *Jpn J Clin Oncol* 2018; **48**: 673-683 [PMID: 29889263 DOI: 10.1093/jjco/hyy077]

75 **Zhang X**, Li M, Chen S, Hu J, Guo Q, Liu R, Zheng H, Jin Z, Yuan Y, Xi Y, Hua B. Endoscopic Screening in Asian Countries Is Associated With Reduced Gastric Cancer Mortality: A Meta-analysis and Systematic Review. *Gastroenterology* 2018; **155**: 347-354.e349 [PMID: 29723507 DOI: 10.1053/j.gastro.2018.04.026]

76 **Castro C**, Dinis-Ribeiro M, Rodrigues ANG, Calheiros T, Santos J, Pereira P, Ramos M, Cunha H, Andrade M, Costa A, Sá L, Antunes L, Bento MJ, Lomba-Viana R. Western long-term accuracy of serum pepsinogen-based gastric cancer screening. *Eur J Gastroenterol Hepatol* 2018; **30**: 274-277 [PMID: 29215432 DOI: 10.1097/MEG.0000000000001040]

77 **Areia M**, Spaander MC, Kuipers EJ, Dinis-Ribeiro M. Endoscopic screening for gastric cancer: A cost-utility analysis for countries with an intermediate gastric cancer risk. *United European Gastroenterol J* 2018; **6**: 192-202 [PMID: 29511549 DOI: 10.1177/2050640617722902]

78 **Quach DT**, Ha DV, Hiyama T. The Endoscopic and Clinicopathological Characteristics of Early-onset Gastric Cancer in Vietnamese Patients *Asian Pac J Cancer Prev* 2018; **19**: 1883-1886 [PMID: 30049355 DOI: 10.22034/APJCP.2018.19.7.1883]

79 **Miwata T,** Quach DT, Hiyama T, Aoki R, Le HM, Tran PLN, Ito M, Tanaka S, Arihiro K, Uemura N, Chayama K. Interobserver and intraobserver agreement for gastric mucosa atrophy. *BMC Gastroenterol* 2015; **15**: 95 [PMID: 26239636 DOI: 10.1186/s12876-015-0327-x]

80 **Jin EH**, Chung SJ, Lim JH, Chung GE, Lee C, Yang JI, Kim JS. Training Effect on the Inter-observer Agreement in Endoscopic Diagnosis and Grading of Atrophic Gastritis according to Level of Endoscopic Experience. *J Korean Med Sci* 2018; **33**: e117 [PMID: 29629520 DOI: 10.3346/jkms.2018.33.e117]

81 **Kodama M**, Okimoto T, Ogawa R, Mizukami K, Murakami K. Endoscopic atrophic classification before and after H. pylori eradication is closely associated with histological atrophy and intestinal metaplasia. *Endosc Int Open* 2015; **3**: E311-E317 [PMID: 26357676 DOI: 10.1055/s-0034-1392090]

82 **Kim YI**, Kook MC, Cho SJ, Lee JY, Kim CG, Joo J, Choi IJ. Effect of biopsy site on detection of gastric cancer high-risk groups by OLGA and OLGIM stages. *Helicobacter* 2017; **22** [PMID: 28940945 DOI: 10.1111/hel.12442]

83 **Yun CY**, Kim N, Lee J, Lee JY, Hwang YJ, Lee HS, Yoon H, Shin CM, Park YS, Kim JW, Lee DH. Usefulness of OLGA and OLGIM system not only for intestinal type but also for diffuse type of gastric cancer, and no interaction among the gastric cancer risk factors. *Helicobacter* 2018; **23**: e12542 [PMID: 30303591 DOI: 10.1111/hel.12542]

84 **Quach DT**, Le HM, Nguyen TS, Hiyama T. The Distribution of Incomplete Gastric Intestinal Metaplasia (GIM) Subtype among Biopsy Sites according to the Updated Sydney System and Its Association with GIM Extension. *Gastroenterol Res Pract* 2018; **2018**: 4938730 [PMID: 29853861 DOI: 10.1155/2018/4938730]

**P-Reviewer:** Amiri M, Nishida T **S-Editor:** Ma RY **L-Editor:** A **E-Editor:** Liu JH

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** Vietnam

**Peer-review report classification**


Grade A (Excellent): 0

Grade B (Very good): B, B


Grade C (Good): 0

Grade D (Fair): 0


Grade E (Poor): 0




**Figure 1 The estimated age-standardized incidence rate for gastric cancer in 2018 (both sexes, all ages)[1].**



**Figure 2 Possibly cost-effective approaches for identifying asymptomatic individuals with a high risk of gastric cancer development.** 1The age-standardized incidence rate is greater than 20 per 100000. 2Applying selective screening for subjects with high-risk pre-endoscopic features. 3Not yet shown to reduce gastric cancer mortality. 4The performance of serum PG I/II ratio should be locally validated. 5Cost-effectiveness should be considered based on the local age-standardized incidence and the cost of esophagogastroduodenoscopy. In multi-ethnic populations, ethnicity-based screening for high-risk ethnic groups should be considered. EGD: Esophagogastroduodenoscopy; UGS: Upper gastrointestinal series; sPGr: Serum PG I/II ratio.



**Figure 3 The age-standardized incidence and mortality rates of gastric cancer[1].** ASR: Age-standardized rate.



**Figure 4 Resource-sensitive approaches to identifying high-risk patients who undergo esophagogastroduodenoscopy for any reason.** WLE: White-light endoscopy; EGA: Endoscopic gastric atrophy; GC: Gastric cancer; IEE: Image-enhanced endoscopy.